P2RY1 Antibody

What is P2RY1 and why is it an important research target?

P2RY1 belongs to the family of G protein-coupled receptors that function as receptors for extracellular ATP and ADP. It plays critical roles in platelet aggregation, inflammatory responses, and insulin secretion. In platelets, P2RY1 activation by ADP leads to mobilization of intracellular calcium via phospholipase C activation, resulting in changes in platelet shape and potential aggregation . In pancreatic beta cells, P2RY1 activation stimulates insulin secretion, with implications for type 2 diabetes research . The receptor is widely expressed throughout the body, particularly in brain tissue, making it relevant for neuroscience research as well .

What tissue types have been validated for P2RY1 antibody applications?

P2RY1 antibodies have been validated across multiple tissue types in various species. Successful applications include:

• Rat brain membranes and thalamus for Western blot and immunohistochemistry

• Human platelet lysates for Western blot analysis

• Rat hippocampal neurons for immunohistochemical staining, particularly in the dentate gyrus region and sub-granular layer

• Rat spinal cord, particularly in layers 1-2 of the dorsal horn

• Human eye tissue

• Rat osteoclasts

• Human pancreatic islets

How do I select the appropriate P2RY1 antibody for my specific research application?

Selection should be based on your experimental needs and validation status for your specific application and species:

• For Western blot analysis: Polyclonal antibodies like APR-009 have been validated for rat brain membranes and human platelets .

• For immunohistochemistry:

  • Fixed-frozen sections work well with antibodies like APR-009 at 1:300 dilution followed by fluorescent secondary antibodies .

  • Consider using blocking peptides (e.g., BLP-PR009) as negative controls to verify specificity .

• For flow cytometry:

  • Directly conjugated antibodies like FITC-anti-P2Y1 (Alomone Labs, APR-021-F) or Alexa Fluor 647-conjugated antibodies are preferable .

  • Validated for use with platelets and transfected cell lines .

• For genetic studies: Consider antibodies validated in tissue from knockout models or those with documented specificity against P2RY1 variants .

How can I optimize immunohistochemical staining protocols for P2RY1 in neural tissues?

Optimizing P2RY1 immunohistochemistry in neural tissues requires careful attention to fixation methods and antibody concentrations:

• Fixation protocol: Perfusion-fixed frozen sections yield excellent results for P2RY1 detection in rat brain and spinal cord. This preserves tissue architecture while maintaining epitope accessibility .

• Antibody dilution: For neural tissues, a 1:300 dilution of anti-P2Y1 receptor antibody (APR-009) has been validated, followed by goat anti-rabbit-AlexaFluor-488 as secondary antibody .

• Counterstaining strategies:

  • DAPI for nuclear visualization works well with fluorescent detection methods .

  • For chromogenic detection, cresyl violet provides effective contrast against P2RY1 staining .

• Specificity controls: Pre-incubation with P2Y1 receptor blocking peptide (BLP-PR009) should be used as a negative control to confirm specificity. This is particularly important in regions with anticipated low expression levels .

• Region-specific considerations: P2RY1 shows distinct expression patterns within neural tissues:

  • Hippocampus: Focus on the sub-granular layer and outer molecular layer of the dentate gyrus .

  • Spinal cord: Concentrate on layers 1-2 of the dorsal horn where immunoreactivity is strongest .

What are the recommended protocols for detecting P2RY1 expression in platelets using flow cytometry?

Flow cytometric analysis of P2RY1 in platelets requires careful sample preparation to prevent activation artifacts:

• Sample preparation:

  • Collect whole blood via cardiac puncture (in mice) or appropriate venipuncture methods for other species

  • Centrifuge at 300 rcf for 3 minutes at room temperature to obtain platelet-rich plasma (PRP)

  • Add PGE₁ (2.5 μM) to prevent platelet activation during the staining procedure

• Staining protocol:

  • For each sample, use 50 μL of PRP

  • Stain with 1 μL of PE-anti-CD41 antibody (0.2 mg/mL) as a platelet marker

  • Add 1 μL of FITC-anti-P2Y1 antibody (Alomone Labs, APR-021-F, 0.2 mg/mL)

  • Incubate for 30 minutes at 4°C in the dark

  • Fix cells with 150 μL of 2% paraformaldehyde post-staining

• Gating strategy:

  • Identify platelets based on size and CD41 positivity

  • Assess P2RY1 expression within the CD41-positive gate

  • Collect at least 10,000 events per sample for reliable quantification

• Controls:

  • Use platelets from P2RY1 knockout mice as negative controls when available

  • Include appropriate isotype controls to establish baseline fluorescence

How can I verify P2RY1 antibody specificity in my experimental system?

Verifying antibody specificity is crucial for reliable P2RY1 research. Multiple complementary approaches should be employed:

• Blocking peptide controls:

  • Pre-incubate the antibody with P2RY1 receptor blocking peptide (e.g., BLP-PR009)

  • Run parallel experiments with blocked and unblocked antibody

  • The blocking peptide should substantially reduce or eliminate specific staining

• Genetic validation:

  • Use tissues from P2RY1 knockout models as negative controls

  • For human studies, utilize cell lines with CRISPR/Cas9-mediated P2RY1 deletion

  • Heterologous expression systems (e.g., HEK293 cells transfected with human P2RY1) serve as positive controls

• Cross-validation with multiple antibodies:

  • Use antibodies targeting different epitopes of P2RY1

  • Concordant results with different antibodies strengthen confidence in specificity

• Functional correlation:

  • Correlate antibody staining with functional assays (e.g., calcium mobilization in response to ADP)

  • In platelets, correlation with shape change and aggregation responses adds functional validation

• Western blot analysis:

  • Confirm the detection of bands at the expected molecular weight

  • Multiple bands may indicate potential post-translational modifications, which should be verified through additional experiments

How does P2RY1 function contribute to inflammatory processes and what methodologies are most suitable for studying this role?

P2RY1 plays a significant role in inflammation, particularly through platelet-leukocyte interactions. Research approaches should consider:

• In vivo inflammatory models:

  • Platelet-specific P2RY1 knockout mice exhibit suppressed leukocyte and platelet recruitment during inflammation, providing a valuable model system

  • These models show 60-70% inhibition of leukocyte recruitment compared to control animals over extended time periods

• Methodological advantages of genetic models over pharmacological approaches:

  • Overcome limitations of antagonist pharmacokinetics

  • Provide better insight into anatomical locality of receptor function

  • Allow adaptation of platelet depletion models to ascertain platelet-specific contributions

• Important experimental considerations:

  • Monitor bleeding times in P2RY1-deficient models, as these mice display severe bleeding phenotypes

  • Assess both platelet and leukocyte numbers, though these are typically not different between control and platelet P2RY1-/- animals

  • Consider both allergic and non-allergic inflammatory models, as P2RY1 has been implicated in both contexts

• Technical approaches for studying P2RY1 in inflammation:

  • Intravital microscopy to visualize leukocyte-endothelial and platelet-endothelial interactions

  • Flow cytometry to quantify platelet-leukocyte aggregates

  • Multiplex cytokine assays to assess inflammatory mediator production

What is the current evidence linking P2RY1 dysfunction to type 2 diabetes, and how can researchers effectively investigate this connection?

Recent functional genomics research has established a novel link between P2RY1 dysfunction and type 2 diabetes (T2D):

• Genetic evidence:

  • Sequencing of P2RY1 in 9,266 participants (including 4,177 with T2D) identified 22 rare variants

  • Seven of these variants were characterized as loss-of-function through in vitro analyses

  • Carriers of these loss-of-function variants, with one exception, exhibited impaired glucose control

• Expression regulation:

  • eQTL analysis in human pancreatic islets (n=103) revealed:

    • Variants in beta-cell enhancer regions linked to increased P2RY1 expression and reduced T2D risk

    • Variants in silent regions associated with decreased P2RY1 expression and increased T2D risk

• Functional studies:

  • P2RY1-specific agonists increased insulin secretion upon glucose stimulation in human pancreatic beta cells (EndoCβH5)

  • Conversely, P2RY1 antagonists decreased glucose-stimulated insulin secretion

  • RNA-seq analysis identified TXNIP as a key transcriptomic marker of insulin secretion triggered by P2RY1 agonist

• Recommended research approaches:

  • Expression analysis of P2RY1 variants using immunofluorescence to assess membrane localization

  • Calcium mobilization assays to evaluate receptor functionality

  • Glucose-stimulated insulin secretion tests with diazoxide to investigate P2RY1's role independent of glucose metabolism

How can researchers accurately characterize loss-of-function P2RY1 variants in relation to cellular localization and signaling capacity?

Characterizing loss-of-function P2RY1 variants requires a systematic approach combining localization and functional studies:

• Cell surface expression analysis:

  • Immunofluorescence experiments to quantify expression levels at the cell membrane

  • Variants like p.L107V, p.K125E, and p.N316S show significantly reduced expression compared to wild-type P2RY1

  • Other variants (p.M75I, p.L99W, p.I130V, p.S252F) may show normal expression but functional defects

• Trafficking assessment:

  • Co-localization studies with ER and Golgi markers to determine if variants are retained in these compartments

  • Surface biotinylation assays to quantify membrane expression

• Functional characterization:

  • Calcium mobilization assays following ADP stimulation

  • MAPK phosphorylation analysis

  • cAMP assays to assess Gq coupling

• Structure-function correlation:

  • Molecular modeling to predict the impact of mutations on receptor structure

  • Cross-species conservation analysis of affected residues

• Experimental design considerations:

  • Include wild-type P2RY1 as positive control

  • Use empty vector transfection as negative control

  • Test multiple concentrations of agonist to generate dose-response curves

  • Assess both basal and stimulated activity

What are the optimal experimental conditions for studying P2RY1-mediated calcium mobilization in different cell types?

Optimizing calcium mobilization studies for P2RY1 requires consideration of cell type-specific factors:

• Platelet studies:

  • Use washed platelets to avoid plasma interference

  • Load with Fura-2 AM (2-5 μM) for 30 minutes at 37°C

  • Maintain calcium in external buffer (typically 1-2 mM)

  • Use ADP as primary agonist (1-10 μM range)

  • Include apyrase (0.32 U/mL) to prevent ATP/ADP degradation

  • Consider P2Y12 receptor antagonists (e.g., AR-C69931MX) to isolate P2RY1-specific responses

• Neuronal cells:

  • For primary hippocampal neurons, a lower concentration of Fura-2 AM (1-2 μM) is typically sufficient

  • Include TTX (0.5-1 μM) to block action potentials when isolating direct P2RY1 effects

  • Consider both ADP and MRS2365 as agonists to verify P2RY1 specificity

  • Use MRS2500 as a specific P2RY1 antagonist for validation

• Pancreatic beta cells:

  • When using EndoCβH5 cells, pre-incubation with diazoxide (250 μM) helps distinguish P2RY1 effects from glucose metabolism

  • Monitor both calcium transients and insulin secretion in parallel

  • Include TXNIP expression analysis as a marker of P2RY1 activation

• Data analysis approaches:

  • Report both peak amplitude and area under curve for calcium responses

  • Normalize to ionomycin (1 μM) response to account for cell-to-cell loading variations

  • Present data as both raw traces and quantification across multiple experiments

How can researchers design experiments to distinguish between P2RY1 and other purinergic receptors that may have overlapping ligand specificity?

Distinguishing P2RY1 from other purinergic receptors requires careful experimental design:

Additional considerations:

• Concentration-response relationships: Different P2 receptors have distinct EC50 values for nucleotides

  • P2RY1: ADP (EC50 ~1 μM)

  • P2Y12: ADP (EC50 ~10 nM)

  • P2X1: ATP (EC50 ~1 μM)

• Downstream signaling discrimination:

  • P2RY1: Primarily couples to Gq (calcium mobilization)

  • P2Y12: Primarily couples to Gi (cAMP inhibition)

  • P2X receptors: Direct ion channels (fast depolarization)

• Temporal resolution: Monitor both fast (milliseconds, typical of P2X) and slower (seconds, typical of P2Y) responses

What considerations are important when designing RNA-seq experiments to investigate P2RY1-mediated transcriptional changes?

RNA-seq experiments investigating P2RY1-mediated transcriptional changes require careful planning:

• Experimental design:

  • Include appropriate controls (vehicle, antagonist pre-treatment, P2RY1-deficient cells)

  • Consider time course experiments (e.g., 1, 4, 24 hours) to capture both early and late transcriptional responses

  • Use selective P2RY1 agonists (e.g., MRS2365) to ensure receptor specificity

  • For studies in beta cells, examine conditions with both normal and high glucose concentrations

• Sample preparation:

  • Ensure high RNA quality (RIN > 8)

  • Include sufficient biological replicates (minimum n=3, preferably n≥5)

  • Consider cell sorting if working with heterogeneous populations

• Data analysis pipeline:

  • Filter for genes with adequate expression (TPM > 1)

  • In P2RY1 agonist studies, focus on significantly regulated genes (upregulated and downregulated)

  • Perform pathway enrichment analysis to identify biological processes affected by P2RY1 activation

  • Validate key findings with qPCR and protein-level studies

• Key pathways to monitor:

  • Nutrient sensing pathways, particularly in beta cells

  • TXNIP and related oxidative stress response genes

  • Calcium-dependent transcription factors

  • Genes involved in secretory processes

• Integration with functional data:

  • Correlate transcriptional changes with functional readouts (e.g., insulin secretion)

  • Consider proteomics to validate translation of key transcriptional changes

  • Use inhibitors of identified pathways to confirm their role in P2RY1-mediated effects

What are common sources of non-specific binding with P2RY1 antibodies and how can these be mitigated?

Non-specific binding is a common challenge with P2RY1 antibodies that can be addressed through several approaches:

• Blocking optimization:

  • For Western blots, test different blocking agents (5% BSA often performs better than milk for phospho-epitopes)

  • For immunohistochemistry, include 5-10% serum from the species of the secondary antibody

  • Consider adding 0.1-0.3% Triton X-100 for better antibody penetration in fixed tissues

• Antibody dilution optimization:

  • Titrate antibodies across a range of dilutions

  • For APR-009, validated dilutions include 1:200 for Western blot and 1:300 for immunohistochemistry

  • For flow cytometry applications, start with manufacturer recommendations (typically 1 μL of 0.2 mg/mL antibody per 50 μL sample)

• Specificity controls:

  • Always include blocking peptide controls when possible

  • Pre-incubation with P2RY1 receptor blocking peptide (BLP-PR009) should eliminate specific staining

  • For flow cytometry, use HEK293 cells transfected with irrelevant constructs alongside P2RY1-transfected cells

• Cross-reactivity mitigation:

  • Be aware of potential cross-reactivity with other P2Y receptor family members

  • Use tissues or cells from P2RY1 knockout models as negative controls when available

  • Consider peptide competition assays with peptides derived from related receptors

• Signal amplification considerations:

  • For low-abundance detection, consider tyramide signal amplification, but be aware this may increase background

  • Biotin-streptavidin systems can amplify signal but may introduce biotin-related background

How should researchers interpret discrepancies in P2RY1 expression patterns between different detection methods?

Discrepancies between detection methods for P2RY1 require systematic troubleshooting:

What alternative approaches can be used when antibody-based detection of P2RY1 proves challenging?

When antibody-based detection is problematic, several alternative approaches can be employed:

• Genetic tagging strategies:

  • CRISPR/Cas9-mediated insertion of epitope tags (FLAG, HA) or fluorescent proteins (GFP, mCherry)

  • Viral transduction of tagged P2RY1 constructs (consider physiological promoters)

  • Transgenic models expressing reporter-tagged P2RY1

• Functional detection methods:

  • Calcium imaging with Fura-2 or GCaMP sensors following ADP or MRS2365 stimulation

  • Bioluminescence resonance energy transfer (BRET) assays to monitor receptor activation

  • Electrophysiological approaches in neurons and other excitable cells

• Transcript-based approaches:

  • RNA-FISH for spatial resolution of mRNA expression

  • Single-cell RNA-seq for cell-type-specific expression profiles

  • Translating ribosome affinity purification (TRAP) for cell-type-specific translatome analysis

• Ligand binding assays:

  • Radioligand binding using [³H]MRS2279 or similar P2RY1-selective antagonists

  • Fluorescent ligand binding with confocal microscopy or flow cytometry

  • Surface plasmon resonance for purified receptor studies

• Mass spectrometry approaches:

  • Targeted proteomics with selected reaction monitoring (SRM)

  • Proximity labeling methods (BioID, APEX) to identify P2RY1-interacting proteins

  • Phosphoproteomics to detect downstream signaling activation

These alternative approaches can complement antibody-based methods or provide solutions when antibodies fail to yield reliable results for P2RY1 detection.